

Joe Lombardo
Governor

Rique Robb
Interim Director



DEPARTMENT OF HUMAN SERVICES



Andrea R. Rivers
Administrator

Ihsan Azzam,
Ph.D., M.D.,
Chief Medical
Officer

KIDNEY DISEASE ADVISORY COMMITTEE

MEETING AGENDA

REGULAR MEETING
January 8, 2026

1:30 p.m. to Adjournment

This meeting is being held virtually. The public are invited to attend.

VIRTUAL INFORMATION

How To Participate

[Meeting Link](#):

Microsoft Teams

[Join the meeting now](#)

Meeting ID: 287 275 605 000

Passcode: Sh957Rm6

[Join by phone](#):

[+1 775-321-6111,,678364365# United States, Reno](#)

[Find a local number](#)

[Phone conference ID: 678 364 365#](#)

For organizers: [Meeting options](#) | [Reset dial-in PIN](#)

NOTICE:

1. The agenda items may be taken out of order.
2. Two or more items may be combined; and
3. Items may be removed from the agenda or delayed at any time.

- 1. Call to Order and Roll Call**
- 2. Public Comment:** No action may be taken on a matter raised under public comment unless the matter itself has been specifically included on an agenda as an action item. To provide public comment telephonically, dial, [+1 775-321-6111](tel:+1775-321-6111). When prompted to provide the meeting ID enter [678364365#](tel:678364365#). Due to time considerations, comments will be limited to five (5) minutes per person. Members of the public utilizing the call-in (audio only) number may raise their hands by pressing *5. Persons making comments will be asked to begin by stating their name for the record, spell their last name, or provide Rory Fuller, rfuller@health.nv.gov, with written comments.
- 3. For Possible Action:** Discussion and possible action to approve the meeting minutes from October 9, 2025.
- 4. For Possible Action:** Discussion and possible action to review any submitted letters of interest and/or applications to KDAC.
- 5. For Information Only:** Status of Grant Applications.
 - *NIH forecast MP-CPI-25-002 Innovative Approaches for Reducing Disparities in Kidney Health*
 - Forecasted with historical date. No Opportunity Package available and no updates posted <https://www.grants.gov/search-results-detail/355825>
 - *NIH PAR-24-074 NIDDK Education Program Grants* (R25 Clinical Trial Not Allowed)
(New applications are due January 30, 2026. Advisory Council Review October 2026. Earliest Start Date December 2026)
- 6. Public Comment:** No action may be taken on a matter raised under this item unless the matter is included on an agenda as an item upon which action may be taken. To provide public comments telephonically, dial [1-775-321-6111](tel:1-775-321-6111). When prompted to provide the meeting ID, enter [678 364 365#](tel:678 364 365#). Due to time considerations, comments will be limited to five (5) minutes. Members of the public utilizing the call-in (audio only) number may raise their hands by pressing *5. People making comments will be asked to begin by stating their name for the record and spelling their last name, or provide Rory Fuller, rfuller@health.nv.gov, with written comments.

7. Adjournment

NOTICES OF THIS MEETING WAS POSTED AT THE FOLLOWING LOCATIONS:

Physical Posting Locations

- Nevada Division of Public and Behavioral Health: 4150 Technology Way, Carson City, NV 89706
- Nevada Division of Public and Behavioral Health: 4126 Technology Way Carson City, NV 89706
- Nevada Health Authority (Las Vegas Office): 500 E Warm Springs Rd, Las Vegas, NV 89119
- Nevada WIC Office: 680 W. Nye Ln., Suite 205, Carson City, NV 89703

Internet Postings

- The Nevada Division of Public and Behavioral Health website at <https://www.dpbh.nv.gov/boards/cwcd-committee-home/2026-cwcd--kdac-meetings/>

and the Department of Administration's website at <https://notice.nv.gov/>

The agenda and meeting information was mailed to groups and individuals as requested. If you need supporting documents for this meeting, please notify Rory Fuller, Division of Public and Behavioral Health, Bureau of Child, Family and Community Wellness, at (775) 684- 2203 or by email at rfuller@health.nv.gov.

We are pleased to make reasonable accommodation for anyone living with a disability and wish to attend the meeting. If special arrangements are necessary, please notify Rory Fuller in writing by email (rfuller@health.nv.gov), by mail (KDAC, Nevada Division of Public and Behavioral Health, 4150 Technology Way, Suite 210, Carson City, NV 89706) or by calling (775) 684-2203 before the meeting date.

If at any time during the meeting a person intending to present on an agenda item cannot do so or is having technical difficulties, please reach out to Rory Fuller, at (775) 684-2203, or by email at rfuller@health.nv.gov referencing the agenda item number, what time the difficulty started, and their intent to participate should the agenda item be moved to another time, date, or addressed otherwise.

Please be cautious and do not click on links in the chat area of the meeting unless you have verified that they are safe. If you ever have questions about a link in a document purporting to be from KDAC, please do not hesitate to contact rfuller@health.nv.gov. Please refrain from commenting in the chat area of the meeting, unless requested to, because minutes are required to be taken of the meeting.

It is the goal of this body to afford the public a comment period in compliance with the minimum requirements of the Open Meeting Law prior to adjournment. This body provides at least two public comment periods. No action may be taken on a matter raised under

public comment unless the item has been specifically included on the agenda as an item upon which action may be taken. The Chair retains discretion to only provide for the Open Meeting Law's minimum public comment and not call for additional item-specific public comment when it is deemed necessary by the Chair to the orderly conduct of the meeting.

This meeting is a public meeting, recorded and held in compliance with and pursuant to the Nevada Open Meeting Law, pursuant to NRS 241. By participating, you consent to recording of your participation in this meeting. All voting members should leave their cameras on for the duration of the meeting and refrain from entering any information into the chat function of the video platform. Please understand the use of obscenities or other behavior which disrupts the meeting to the extent that its orderly conduct is made impractical may result in the forfeiture of the opportunity to provide public comment or removal from the meeting.

Additionally, anyone who would like to be on the mailing list must submit a written request every six (6) months to the Nevada Division of Public and Behavioral Health at the address listed below. KDAC, DPBH, Attn: Anais Infante 4150 Technology Way, Suite 210 Carson City, Nevada 89706.

KDAC, DPBH, Attn: Rory Fuller
4150 Technology Way, Suite 210
Carson City, Nevada, 89706

If you would like to receive updates and agenda postings directly through email, please register for the Kidney Disease Advisory Committee Listserv by sending an email to the following link:

KDAC-Subscribe-request@listserv.state.nv.us

Attachment for Agenda Item #3

Joe Lombardo
Governor

Rique Robb
Interim Director



DEPARTMENT OF HUMAN SERVICES



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH



Andrea R. Rivers,
MS
Administrator

Ihsan Azzam,
Ph.D., M.D.
*Chief Medical
Officer*

KIDNEY DISEASE ADVISORY COMMITTEE (KDAC)

DRAFT MEETING MINUTES

Date: October 9, 2025

Time: 1:30 PM - Adjournment

Location: Virtual via Microsoft Teams

ATTENDEES:

Members Present:

Dr. Krista Schonrock, chair
Dr. Larry Lehrner
Rayleen Earney
Beth Britton

Members not Present:

Katrina Russell
Justin Iorri

Others present:

Rory Fuller, DPBH CDPHP Staff

Amber Hise, CDPHP Section Manager.

Michelle Harden, CDPHP

Bryan Davis, CDPHP

Taylor Moseley CDPHP

Dillon Winkelmann, CDPHP

Anais Infante, DPBH

Troy Lovick, CDPHP

Tammera Brower, DPBH

Darlene Douthitt, CDPHP

Godwin Nwando, CDPHP

Oscar Fernandez, DPBH

Taliman Afroz, CDPHP

Donadya McCullough, CDPHP

Sarah Rogers, DPBH

Cade Grogan

Keibi Mejia

Anakaren Lamas, CDPHP

AGENDA ITEMS:

1. Call To Order and Roll Call

Rory Fuller called the roll and confirmed quorum; four of six members were present.

2. Public Comment: First public comment period

No Public comments were made during this period.

3. Discussion and possible action to approve the meeting minutes of June 3, 2025 – Dr. Krista Schonrock, Chair

Dr. Schonrock moved to approve the minutes of the previous meeting, no edits were suggested, and the motion was seconded by Rayleen Earney. The minutes of the June 3, 2025, meeting were unanimously approved.

4. For Possible Action: Discussion and possible action to review and approve KDAC membership applications.

DPBH staff Rory Fuller reported that no applications have been received for the current Request for Information (RFI). DPBH staff Michelle Harden added that continued circulation of the RFI would be beneficial for finding more members.

No action was taken by the council members at this time.

5. For Possible Action: Discussion and possible action to review and remove inactive members.

DPBH staff Rory Fuller informed the committee that Justin Iorri had not attended a meeting in more than a year and that multiple attempts to contact him by email, social media, and telephone had gone unanswered. The committee discussed the importance of maintaining a patient perspective on the committee; however, ongoing challenges in achieving quorum have reduced the committee's effectiveness in serving the public.

Dr. Lehrner moved to remove Justin Iorri as a member. Rayleen Earney seconded the motion, and the motion passed unanimously.

6. For Possible Action: Discussion and possible action on potential grants and cooperative agreements of interest to KDAC to support and address kidney disease

DPBH Staff Michelle Harden outlined the committee's role in promoting grants related to kidney disease and health promotion and brought awareness to two potential grant opportunities through the National Institute of Health for the committee to consider acting on.

(forecast) MP-CPI-25-002 Innovative Approaches for Reducing Disparities in Kidney Health

(posted) PAR-24-074 NIDDK Education Program Grants (R25 Clinical Trial Not Allowed) -- <https://grants.nih.gov/grants/guide/pa-files/PAR-24-074.html>

Dr. Schonrock motioned to proceed with the grant application, seconded by Rayleen Earney. The motion was passed unanimously, and the applications were reviewed and discussed at the next scheduled meeting.

7. Public Comment: Second public comment period

DPBH Staff Rory Fuller commented that there is a new Listserv for the Kidney Disease Advisory Committee, and the link to subscribe is included in this meeting's agenda and will be included in future agendas.

8. Adjournment:

Dr. Lehrner motioned to adjourn, second by Rayleen Earney, motion passed unanimously, the meeting was adjourned at 2:01 Pm

Next meeting:

January 8, 2026

1:30 Pm – Adjournment

Location: Virtual via teams

Quarterly meeting

Minutes prepared by Rory Fuller using the following reference.

Robert, H. (2020). *Robert's rules of order: Newly revised (12th ed.)*. Da Capo Press.

Nevada Revised Statute. *Open Meeting Law (NRS 241)*.

Attachment for Agenda Item #4

George Jarad, MD

Nephrology, Intermountain Kidney Services

St. George, Utah

July 31, 2025

To the Nevada Division of Public and Behavioral Health,

I am very interested in joining the “Advisory Committee on Grants for Addressing Race-Based Health Disparities Relating to Kidney Diseases”.

I am a nephrologist with more than 18 years of clinical experience. I moved last year to Southern Utah, as I fell in love with the desert and its people. I am currently employed by Intermountain Kidney Services (IKS). Our main office is in St. George, UT. Because of the unique geographic location, we take care of significant number of patients from Nevada, and we staff one of the very few rural dialysis centers in rural Nevada. The center is in Mesquite, NV. After extensive lobbying within Intermountain, recently, we were able to start a nephrology clinic in Mesquite.

Throughout my professional life, initially at Washington University in St. Louis, and currently at IKS, I have been fortunate enough to work and learn from great mentors. I have taken care of patients with different backgrounds, some from inner cities, and many patients who live in rural communities. Those patients have different ethnic and socioeconomical backgrounds. I was luck to be able to follow patients with kidney diseases throughout different stages of kidney disease, including significant number of dialysis patients. I have evaluated patients for kidney transplants and evaluated kidney donors. I was also lucky to be able to take care of many kidney transplant patients and learn the intricacies of managing immunosuppression after transplantation.

Throughout my career, I was struck by the significant disparity in access to specialized services, including nephrology services. These disparities tend to affect the most vulnerable population, usually the old and the poor. The disparity is even more obvious in minorities, especially those who do not speak English well. I saw the same pattern in big cities and in rural areas, in Missouri and now in Southern Utah and Nevada.

The main cause of such disparities is similar between big cities and rural desert communities. Access to specialized services is difficult, expensive and time-consuming. Lack of knowledge and poor health literacy delays seeking medical attention. Further, lack of trust and poor experience with the health care system, whether personal or witnessed, exacerbates such disparity.

Delayed referrals to nephrologists are associated with worse patient outcomes as we usually miss the short window to intervene to treat the cause of kidney dysfunction. This is not only detrimental to patient health but can also deepen the fragile trust in the healthcare system and providers. Moreover, delayed presentation, especially if emergent dialysis is needed, is vastly more expensive for health care. Therefore, the disparity is harmful to patients and their family and adds significant cost to healthcare system. Improving health care access to underserved communities may have significant impact on these communities and may reduce the overall cost of healthcare.

If chosen to serve on the committee, I will bring significant knowledge and expertise in the field and will be an advocate for patients, their caregivers and the healthcare workers who care for them. I will be open-minded to review any proposal and give honest and constructive feedback to try to improve it, if necessary. I will work to foster more collaboration between health workers in the field and specialists who, like me, tend to practice in larger communities.

Sincerely,

A handwritten signature in black ink, consisting of a stylized line that forms a 'G' and 'J', followed by a small circle for the dot of the 'J', and then a long, sweeping line that ends with a small circle for the dot of the 'A' in 'Jarad'. To the right of this signature is a large, empty oval space for a handwritten name.

George Jarad, MD

CURRICULUM VITAE

George Jarad

Personal Data

Work Address:

Washington University School of Medicine
Intermountain Kidney Services (IKS), St. George
1490 Foremaster Drive, Suite350
St. George, UT 84790

Work Phone:

Personal Phone:

e-mail:

Education

Medical School: Damascus University, 1987- 1993

Residency: Internal Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, and 1997 -2000. Supervisor: Michael J. McFarlane, MD

Fellowship: Case Western Reserve University, University Hospital/VA of Cleveland & MetroHealth Medical Center, Cleveland, OH, 2000-2003. Supervisor: Donald E. Hricik, MD

Post-Doctoral Fellowship: Renal Division, Washington University School of Medicine, St Louis, MO, Nov, 2005-June, 2007. Supervisor: Jeffery H. Miner, PhD

Employment

Research Associate: Renal Division, MetroHealth Medical Center Cleveland, OH. July-2003 - Dec/2003

Research Associate: Renal Division, Washington University School of Medicine, St. Louis, MO. Jan/2004 - Oct/2005

Instructor in Medicine: Renal Division, Washington University School of Medicine, St. Louis, MO. July/2007 - June/2010

Assistant Professor of Medicine: Renal Division, Washington University School of Medicine, St. Louis, MO. July/2010 - Dec/2017

Associate Medical Director: Forest Park Dialysis Center, Washington University School of Medicine, St. Louis, MO, July/2014 - June/2017

Medical Director: Forest Park Dialysis Center, Washington University School of Medicine, St. Louis, MO, July/2017 - Present

Associate Professor of Medicine: Division of Nephrology, Washington University School of Medicine, St. Louis, MO, Jan/2018 – June/2024.

Staff Nephrologist: Intermountain Kidney Services (IKS), St. George, UT, June/2025-Current

Honors and Awards

- American board of Nephrology, Diplomate in Nephrology, 2003

Professional society memberships:

- American Society of Nephrology

Medical Licenses:

- Utah
- Nevada

Work Experience:

Throughout my training and clinical practice at Washington University, I accumulated wide range of experiences. While I started my professional career in basic research, I transitioned to a clinical faculty and have practiced nephrology in different setting for more than 18 years:

- While not trained as a transplant nephrologist, I worked very closely with the kidney transplant team at Washington University for more than 16 years:
 - Evaluated patients for kidney transplant.
 - Managed transplant patients in post-transplant clinic, including managing immunosuppression, referring for biopsy and treatment of rejection.
 - Managed patients with failing renal allograft and patients with chronic kidney diseases after other organ transplant (bone marrow, lung, heart and liver).
- Extensive experience with different dialysis modalities:
 - Medical director of the Forest Park Dialysis Center between 2017-2024. I was associate director from 2014 until 2017.
 - Expert with incenter hemodialysis, including working closely with vascular surgeon to establish dialysis access (AVF and AVG), revising vascular access protocols and implementing quality improvement initiatives to reduce the rate of blood stream infection.
 - Accumulated significant expertise with Peritoneal Dialysis (PD). I particularly enjoy trouble shooting complex cases and prolonging the life of the peritoneal membrane.
 - I believe home dialysis modalities, whether home HD, and especially PD are underutilized, especially in rural and underserved communities. Better relationship between providers and their patients, in addition to improved multidisciplinary approach and education programs can increase the number of patients doing dialysis at home.
 - Special interest in Continuous Renal Replacement Therapies (CRRT), including CVVH, CVVHD and CVVHDF, using different machines (Primaflex, Nxstage)
 - Extensive experience with Slow Low Efficiency Dialysis (SLED), whether it is for inpatient use or for outpatient home hemodialysis use.
- Caring for complex patients with acute and chronic kidney diseases (AKI and CKD):
 - Managed patients in the medical, surgical and cardiothoracic ICU with AKI and severe electrolyte abnormalities, with and without need for Renal Replacement Therapy.
 - My current outpatient practice focus on patients with wide range of kidney diseases, especially proteinuric kidney diseases, glomerulonephritis, diabetic kidney diseases and patients with CKD after organ transplant.
- Due to my basic science background, I have been caring for increasing number of patients with hereditary kidney diseases, especially Alport syndrome, polycystic kidney diseases and familial FSGS. At Washington University, I had the privilege of caring for multiple generations from the same family, which gave me better insight into the complex nature of these diseases and better understanding of family dynamics.

Professional Service

2017, MRMC Broad Agency Announcement for Extramural Medical Research, Combat Casualty Care

review committee

2017, Nephcure Ad Hoc review committee

2019, Nephcure Ad Hoc review committee

2021, Nephcure Ad Hoc review committee

2022, Moderator. Annual Dialysis Conference “Peritoneal Dialysis Access”

Publications

1. Khan S, Konieczkowski M, Koepke A, **Jarad G**, Schlessman K, Schelling JR. Apoptosis and JNK activation are differentially regulated by Fas expression level in renal tubular epithelial cells. *Kidney Int*, 60:65-76, 2001.
2. **Jarad G**, Wang B, Miao H, Khan S, Wu K, DeVore J, Nishimura SL, Wible BA, Konieczkowski M, Sedor JR, Schelling JR. Fas activation induces renal tubular Epithelial cell β 8 integrin expression and function in the absence of apoptosis. *J Biol Chem*, 277:47826-47833, 2002.
3. Wu K, Khan S, Lakhe-Reddy S, Wang L, **Jarad G**, Miller RT, Konieczkowski M, Brown AM, Sedor JR, Schelling JR. Renal tubular epithelial cell apoptosis is associated with caspase cleavage of the NHE1 Na^+/H^+ exchanger. *Am J Physiol*, 284:F1-F11, 2002.
4. **Jarad G**, Jeffery Simeske, John R Sedor, Jeffrey Schelling. Nucleic acid-based techniques for post-transcriptional regulation of molecular targets. *Curr Opin Nephrol Hypertens*, 12:415-421, 2003.
5. Wu KL, Khan S, Mukherjee A, Lakhe-Reddy S, **Jarad G**, Obejero-Paz CA, Konieczkowski M, Sedor JR, Schelling JR. The NHE1 Na^+/H^+ exchanger recruits ERM proteins to regulate Akt-dependent cell survival. *J Biol Chem*, 279:26280-26286, 2004.
6. **Jarad G**, Lakhe-Reddy S, Blatnik J, Koepke M, Khan S, El-Meanawy M A, Oconnor AS, Sedor JR, Schelling JR. Renal phenotype is exacerbated in *Os* and *lpr* double mutant mice. *Kidney Int*, 66:1026-1035, 2004.
7. Miner JH, Go G, Cunningham J, Patton BL, **Jarad G**. Transgenic isolation of skeletal muscle and kidney defects in laminin beta2 mutant mice: Implications for Pierson syndrome. *Development*, 133:967-975, 2006
8. El-Aouni S, Herbach N, Blattner SM, Henger A, Rastaldi MP, **Jarad G**, Miner JH, Moeller MJ, Luckow B, Dedhar S, Holzman LB, Wanke R, Kretzler M. Podocyte specific deletion of Integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. *J Am Soc Nephrol*, 17:1334-1344, 2006
9. Lakhe-Reddy S, Khan S, Konieczkowski M, **Jarad G**, Wu KL, Reichardt LF, Takai Y, Bruggeman LA, Wang B, Sedor JR, Schelling JR. β 8 integrin regulates mesangial cell differentiation by RhoGDI-dependent Rac activation. *J Biol Chem*, 281:19688-19699, 2006
10. **Jarad G**, Cunningham J, Shaw AS, Miner JH. Proteinuria precedes podocyte foot process effacement in *Lamb2*-/- mice, implicating the GBM as a barrier to albumin. *J Clin Invest*, 116:2272-2279, 2006
11. Harvey SJ, **Jarad G**, Cunningham J, Rops, van der Vlag J, Berden JH, Moeller MJ, Holzman LB, Burgess RW, Miner JH. Disruption of Glomerular Basement Membrane Charge Through Podocyte-Specific Mutation of Agrin Does Not Alter Glomerular Permselectivity. *Am J Pathol*, 171:139-152, 2007
12. Pozzi A, **Jarad G**, Moeckel GW, Coffa S, Zhang X, Gewin L, Eremina V, Hudson BG, Borza DB, Harris RC, Holzman LB, Phillips CL, Fassler R, Quaggin SE, Miner JH, Zent R. Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity. *Dev Biol*, 316:288-301, 2008
13. Podocyte-specific deletion of Dicer alters cytoskeletal dynamics and causes rapidly progressive glomerulonephritis. Harvey SJ, **Jarad G**, Cunningham J, Goldberg S, Schermer B, Harfe BD, Michael T, MT, Benzing T, Miner JH. *J Am Soc Nephrol*, 19:2150-2159, 2008.
14. Laminins promote postsynaptic maturation by an autocrine mechanism at the neuromuscular junction. Nishimune H, Valdez G, **Jarad G**, Moulson CL, Müller U, Miner JH, Sanes JR. *J Biol Chem*, 182:1201-1215, 2008

15. Albuminuria, Wherefore art thou? **Jarad G**, Miner JH. *J Am Soc Nephrol*, 20:455-457, 2009
16. Update on the glomerular filtration barrier. **Jarad G**, Miner JH. *Curr Opin Nephrol Hypertens*. 18:226-232, 2009
17. The Pax3-Cre transgene exhibits a rostrocaudal gradient of expression in the skeletal muscles lineage. **Jarad G**, Miner, JH. *Genesis*. 47, 1-6, 2009.
18. A new function for parietal epithelial cells: a second glomerular barrier. Ohse T, Chang AM, Pippin JW, **Jarad G**, Hudkins KL, Alpers CE, Miner JH, Shankland SJ. *Am. J. Physiol. Renal Physiol*. 297: F1566-1574, 2009.
19. Activation of NFAT Signaling in Podocytes Causes Glomerulosclerosis. Wang Y, **Jarad G**, Tripathi P, Pan M, Cunningham J, Martin DR, Liapis H, Miner JH, Chen F. *J Am Soc Nephrol*. 21: 1657-1666, 2010.
20. Dystroglycan does not contribute significantly to kidney development or function, in health or after injury. **Jarad G**, Pippin JW, Shankland SJ, Kreidberg J, Miner JH. *Am. J. Physiol. Renal Physiol*. 300: F811-820, 2011. PMCID: PMC3064129
21. Forced expression of laminin beta1 in podocytes prevents nephrotic syndrome in mice lacking laminin beta2, a model for Pierson syndrome. Suh JH, **Jarad G**, Vandervoorde RG, Miner JH. *Proc Natl Acad Sci USA*, 108: 15348-15353, 2011: PMCID: PMC3174642
22. Albumin-associated free fatty acids induce macropinocytosis in podocytes. Chung JJ, Huber TB, Gödel M, **Jarad G**, Hartleben B, Kwoh C, Keil A, Karpitskiy A, Hu J, Huh CJ, Cella M, Gross RW, Miner JH, Shaw AS. *J Clin Invest*, 125:2307-16, 2015
23. Albumin contributes to kidney disease progression in Alport syndrome. **Jarad G**, Russell H. Knutson, Robert P. Mecham, and Jeffrey H. Miner. *Am. J. Physiol. Renal Physiol*, 311, F120-130, 2016
24. Klotho regulation by albuminuria is dependent on ATF3 and endoplasmic reticulum stress Delitsikou V, **Jarad G**, Rajaram RD, Ino F, Rutkowski JM, Chen CD, Santos CXC, Scherer PE, Abraham CR, Shah AM, Feraille E, Miner JH, de Seigneux S. *FASEB*, 34, 2087-2104, 2020
25. Blocking CHOP-dependent TXNIP shuttling to mitochondria attenuates albuminuria and mitigates kidney injury in nephrotic syndrome. Sun-Ji Park, Yeawon Kim, Chuang Li, Junwoo Suh, Jothilingam Sivapackiam, Tassia M. Goncalves, **George Jarad**, Guoyan Zhao, Fumihiko Urano , Vijay Sharma, and Ying Maggie Chen. *PNAS*, 119, e2116505119, 2022.